Oral Immunotherapy for Peanut Allergy in Children 1 to Less Than 4 Years of Age.


Journal

NEJM evidence
ISSN: 2766-5526
Titre abrégé: NEJM Evid
Pays: United States
ID NLM: 9918317485806676

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 7 2 2024
pubmed: 7 2 2024
entrez: 6 2 2024
Statut: ppublish

Résumé

Oral Immunotherapy for Peanut Allergy in ChildrenThis trial enrolled children 1 to <4 years of age who had allergic symptoms from peanut protein during screening. Participants received peanut allergen powder-dnfp (PTAH) or placebo for approximately 12 months; 73.5% of participants receiving PTAH tolerated a single dose of ≥600 mg peanut protein versus 6.3% of the placebo group.

Identifiants

pubmed: 38320526
doi: 10.1056/EVIDoa2300145
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

EVIDoa2300145

Auteurs

George Du Toit (G)

Guy's and St. Thomas' National Health Service Foundation Trust and Kings College, London.

Kari R Brown (KR)

Aimmune Therapeutics, Nestlé Health Science, Brisbane, CA.

Andrea Vereda (A)

Aimmune Therapeutics, Nestlé Health Science, London.

Anne-Marie Irani (AM)

Aimmune Therapeutics, Nestlé Health Science, Brisbane, CA.

Stephen Tilles (S)

Aimmune Therapeutics, Nestlé Health Science, Brisbane, CA.

Anoshie Ratnayake (A)

Aimmune Therapeutics, Nestlé Health Science, Brisbane, CA.

Stacie M Jones (SM)

University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock.

Brian P Vickery (BP)

Emory University School of Medicine, Atlanta.

Classifications MeSH